Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
Arch. Neurol., Dec;66(12):1517-22 (2009)
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.
Arch. Neurol., Sep;67(9):1116-22 (2010)
Lack of familial aggregation of Parkinson disease and Alzheimer disease.
Arch. Neurol., Jul;61(7):1033-9 (2004)
Implantation of bilateral deep brain stimulators in patients with Parkinson disease and preexisting cardiac pacemakers. Report of two cases.
J. Neurosurg., Dec;101(6):1073-7 (2004)
Contribution of aging to the severity of different motor signs in Parkinson disease.
Arch. Neurol., Mar;62(3):467-72 (2005)
A technique for minimally altering anatomically based subthalamic electrode targeting by microelectrode recording.
Neurosurg Focus., 20(5):E8 (2006)
Essential tremor associated with pathologic changes in the cerebellum.
Arch. Neurol., Aug;63(8):1189-93 (2006)
Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations.
Mov. Disord., Mar;23(4):588-92 (2008)
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.
J Clin Exp Neuropsychol., Aug;32(7):775-9 (2010)
Familial aggregation of early- and late-onset Parkinson's disease.
Ann. Neurol., Oct;54(4):507-13 (2003)
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Arch. Neurol., Jul;61(7):1044-53 (2004)